Bioavailability and bioequivalence of dermatological formulations

Dermatological and Transdermal Formulations

Volumn , Issue , 2002, Pages 401-498

  Surber, Christian ^a   Davis, Adrian F ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052255310     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (482)

1. Melnick D, Hochberg M, Oser BL. Physiological availability of vitamins. I. The human bioassay technique. J Nutr 30:67-79, 1945.
2. Morrison AB, Chapman DG, Campbell JA. Further studies on the relation between in vitro disintegration time of tablets and the urinary excretion rates of riboflavin. J Am Pharm Assoc Sci Ed 48:634-637, 1959.
3. Morrison AB, Campbell JA. The relationship between physiological availability of salicylates and riboflavin and in vitro disintegration time of enteric coated tablets. J Am Pharm Assoc Sci Ed 49:473-478, 1960.
4. Levy G. Comparison of dissolution and absorption rates of different commercial aspirin tablets. J Pharm Sci 50:388-392, 1961.
5. Middleton EJ, Davies JM, Morrison AB. Relationship between rate of dissolution, disintegration time, and physiological availability of riboflavin in sugar-coated tablets. J Pharm Sci 53:1378-1380, 1964.
6. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD. Outbreak of anticonvulsant toxicity in an Australian city. Br Med J 4:271-273, 1970.
7. Danon A, Horowitz J, Ben-Zvi Z. An outbreak of digoxin intoxication. Clin Pharmacol Ther 21:643-646, 1977.
8. Melikian AP, Straughn AB, Slywka GWA, Whyatt PL, Meyer MC. Bioavailability of eleven phenytoin products. J Pharmacokinet Biopharm 5:133-146, 1977.
9. Glazko AJ, Kinkel AW, Alegnani WC, Holmes EL. An evaluation of absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol 9:472-483, 1968.
10. Flynn GL, Weiner ND. Topical and transdermal delivery—provinces of realism. In: Gurny R, Teubner A, eds. Dermal and Transdermal Drug Delivery. Stuttgart: Wissen- schaftliche Verlagsgesellschaft, pp 33-65, 1993.
11. Somberg JC. Bioequivalence or therapeutic equivalence. J Clin Pharmacol 26:1,1986.
12. Dettelbach HR. A time to speak out on bioequivalence and therapeutic equivalence. J Clin Pharmacol 26:307-308, 1986.
13. Lamy PP. Generic equivalents: issues and concerns. J Clin Pharmacol 26:309-316, 1986.
14. Dupuis D, Rougier A, Roguet R, Lotte C, Kalopissis G. In vivo relationship between horny layer reservoir effect and percutaneous absorption in human and rat. J Invest Dermatol 82:353-356, 1984.
15. Guzek DB, Kennedy AH, McNeill SC, Wakshull E, Potts RO. Transdermal drug transport and metabolism. I. Comparison of in vitro and in vivo results. Pharm Res 6:33-39, 1989.
16. Schalla W, Jamoulle J-C, Schaefer H. Localization of compounds in different skin layers and its use as an indicator of percutaneous absorption. In: Bronaugh RL, Mai- bach HI, eds. Percutaneous Absorption. 2nd ed. New York: Marcel Dekker, pp 283-312, 1989.
17. Surber C. Drug concentration in the skin. In: Maibach HI, ed. Dermatologic Research Techniques. Boca Raton: CRC Press, pp 151-178, 1996.
18. Metzler CM. Statistical criteria. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical Bioequivalence. New York: Marcel Dekker, pp 35-66, 1991.
19. Hauck WW. Bioequivalence studies of topical preparations: statistical considerations. Int J Dermatol 31(suppl 1):29-33, 1992.
20. Rauws AG. Bioequivalence: a European community regulatory perspective. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical Bioequivalence. New York: Marcel Dekker, pp 419-441, 1991.
21. FDA, Center for Drug Evaluation and Research. GUIDANCE: Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. Rockville, MD: Division of Bioequivalence, 1995.
22. Stoughton RB. Vasoconstrictor assay: specific applications. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel: S Karger, pp 42-53, 1992.
23. Smith EW, Meyer E, Haigh JM. Accuracy and reproducibility of the multiple-reading skin blanching assay. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel: S Karger, pp 65-73, 1992.
24. Aalto-Korte K. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol 133:403-408, 1995.
25. Anderson S, Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Commun Stat Theor Method 12:2663-2692, 1983.
26. Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two- group comparative bioavailability trials. J Pharmacokinet Biopharm 12:83-91, 1984.
27. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15:657-680, 1987.
28. Steinijans VW, Hauschke D, Jonkman JHG. Controversies in bioequivalence studies. Clin Pharmacokinet 22:247-253, 1992.
29. Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol 30:181-187, 1992.
30. Skelly JP, Shah VP, Maibach HI, Guy RH, Wester RC, Flynn GL, Yacobi A. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 4: 265-267, 1987.
31. Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci 51:802-804, 1962.
32. Shah VP, Elkins J, Hanus J, Noorizadeh C, Skelly JP. In vitro release of hydrocortisone from topical preparations and automated procedure. Pharm Res 8:55-59, 1991.
33. Neubert R, Wohlrab W. In vitro methods for biopharmaceutical evaluation of topical formulations. Acta Pharm Technol 36:197-206, 1990.
34. FDA, Center for Drug Evaluation and Research. Interim Guidance. Topical Corticosteroids: In Vivo Bioequivalence and In Vitro Release Methods. Rockville, MD: Division of Bioequivalence, 1992.
35. United States Pharmacopeia. Vol. XXII. Rockville, MD: United States Pharmacopeial Convention, 1990.
36. Shah VP, Tymes NW, Yamamoto LA, Skelly JP. In vitro dissolution profile of transdermal nitroglycerin patches using paddle method. Int J Pharm 32:243-250, 1986.
37. Shah VP, Tymes NW, Skelly JP. Comparative in vitro release profiles of marketed nitroglycerin patches by different dissolution methods. J Control Release 7:79-86, 1988.
38. Shah VP, Tymes NW, Skelly JP. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches. Pharm Res 6:346-351, 1989.
39. Reddish G, Wales H. Antiseptic action of USP and NF ointments. J Am Pharm Assoc 18:576-578, 1929.
40. Christoff K. Einfluss der oberflachenaktiven Substanzen OAS auf die strukturrheo- logischen Eigenschaften der Salbengrundlagen und die Abgabeschwindigkeit von Arz- neimitteln. Pharmazie 22:251-253, 1967.
41. Clark G, Davies G. A new method for measuring diffusion of antiseptics from ointment bases. Br J Dermatol 1:521-525, 1949.
42. Unna P. Zur frage der salbengrundlagen. Dtsch Med Wochenschr 51:197-199, 1926.
43. Poulsen BJ, Young E, Coquilla V, Katz M. Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester. J Pharm Sci 57: 928-933, 1968.
44. Loth H, Holla-Benninger A. Untersuchungen der arzneiliberation aus Salben. 1. Mit- teilung: entwicklung eines in vitro Liberationmodells. Pharm Ind 40:256-261, 1978.
45. De Vos A, Vervoort L, Kinget R. Release of indomethacin from transparent oil-waters gels. J Pharm Sci 83:641-643, 1994.
46. Bottari F, Di Colo G, Nannipieri E, Saettone MF, Serafini MF. Influence of drug concentration on in vitro relase of salicylic acid from ointment bases. J Pharm Sci 63:1779-1783, 1974.
47. Delonca H, Chanal JL, Maillols H, Ghebbi R. Methode d’etude in vitro des preparations cutanees semi-solides. Comparisons in vitro-in vivo. Pharm Acta Helv 52:5164, 1977.
48. Guy RH, Fleming R. The estimation of diffusion coefficients using the rotating diffusion cell. Int J Pharm 3:143-149, 1979.
49. Touitou E, Abed L. The permeation behavior of several membrane with potential use in the design of transdermal devices. Pharm Acta Helv 60:193-198, 1985.
50. Hadgraft J, Walters KA, Wotton PK. Facilitated percutaneous absorption: a comparison and evaluation of two in vitro models. Int J Pharm 32:257-263, 1986.
51. Velissaratou AS, Papaioannou G. In vitro release of chlorpheniramine maleate from ointment bases. Int J Pharm 52:83-86, 1989.
52. Davis A. Novel formulations for improved therapy. PhD dissertation, University of Wales, College of Cardiff, 1995.
53. Shah VP, Elkins J, Lam SY, Skelly JP. Determination of in vitro drug release from hydrocortisone creams. Int J Dermatol 53:53-59, 1989.
54. Shah VP, Elkins J, Skelly JP. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams. J Pharm Sci 81:104-106, 1992.
55. Shah VP, Skelly JP. Practical considerations in developing a quality control (in vitro release) procedure for topical drug products. In: Shah VP, Maibach HI, eds. Topical Drug Bioavailability, Bioequivalence, and Penetration. New York: Plenum Press, pp 107-117, 1993.
56. Behme RJ, Kensler TT, Brooke D. A new technique for determining in vitro release rates of drugs from creams. J Pharm Sci 71:1303-1305, 1982.
57. Corbo M, Schultz TW, Wong GK, Van Buskirk GA. Development and validation of in vitro release testing methods for semisolid formulations. Pharm Technol (Sept): 112-128, 1993.
58. Guy RH, Hadgraft J. On the determination of drug release rates from topical dosage forms. Int J Pharm 60:R1-R3, 1990.
59. Rolland A, Demichelis G, Jamoulle J-C, Shroot B. Influence of formulation, receptor fluid, and occlusion, on in vitro drug release from topical dosage forms, using an automated flow-through diffusion cell. Pharm Res 9:82-86, 1992.
60. Fares HM, Zatz JL. Measurement of drug release from topical gels using two types of apparatus. Pharm Technol (Jan):54-56, 1995.
61. Flynn GL. Comparisons between in vitro techniques. Acta Pharm Suec 20:54-55, 1983.
62. Poulsen BJ, Flynn GL. In vitro methods used to study dermal delivery and percutaneous absorption. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. New York: Marcel Dekker, pp 431-459, 1985.
63. Barry BW. Dermatological Formulations. New York: Marcel Dekker, 1983.
64. Addicks W, Weiner N, Flynn G, Curl R, Topp E. Topical drug delivery from thin applications: Theoretical predictions and experimental results. Pharm Res 7:1048-1054, 1990.
65. Flynn GL, Smith RW. Membrane diffusion III: Influence of solvent composition and permeant solubility on membrane transport. J Pharm Sci 61:61-66, 1972.
66. Tanaka S, Takashima Y, Murayama H, Tsuchiya S. Studies on release from ointments: V. Release of hydrocortisone butyrate propionate from topical dosage forms to silicone rubber. Int J Pharm 27:29-38, 1985.
67. Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int J Pharm 76:1-8, 1991.
68. Hadgraft J, Ridout G. Development of model membranes for percutaneous absorption measurements. II. Dipalmitoyl phosphatidylcholine, linoleic acid and tetradecane. Int J Pharm 42:97-104, 1988.
69. Buchmann S. Entwicklung eines in vitro absorptionmodelles auf der basis von zell- kulturen. Basel: University of Basel, 1987.
70. Steinstrasser I. The organized HaCaT cell culture sheet: a model approach to study epidermal peptide drug metabolism. Zurich: ETH Zurich, 1994.
71. Williams RL. Bioequivalence of topical corticosteroids: a regulatory perspective. Semin Dermatol 31(suppl 1):2-5, 1992.
72. Beastall J, Guy RH, Hadgraft J, Wilding I. The influence of urea on percutaneous absorption. Pharm Res 3:294-297, 1986.
73. Lippold BC, Teubner A. Biopharmazeutische qualitat von Arzneiformen, insbesondere fur lokale Anwendung, abgeleitet aus Wirkungsmessungen. Pharm Ind 43:71-73, 1981.
74. Lippold BC, Teubner A. Einfluss verschiedener salbengrundlagen auf die Wirkung von Nicotinsaurebenzylester in losungssalben. Pharm Ind 43:1123-1133, 1981.
75. Lippold BC, Reimann H. Wirkungsbeeinflussung bei losungssalben durch Vehikel am beispiel von Methylnicotinat. Acta Pharm Technol 3:136-142, 1989.
76. Katz M, Poulsen BJ. Corticoid, vehicle, and skin interaction in percutaneous absorption. J Soc Cosmet Chem 23:565-590, 1972.
77. Caron D, Queille-Roussel C, Shah VP, Schaefer H. Correlation between the drug penetration and the blanching effect of topically applied hydrocortisone creams in human beings. J Am Acad Dermatol 23:458-462, 1990.
78. Kaiho F, Nomura H, Makabe E, Kato Y. Percutaneous absorption of indomethacin from mixtures of fatty alcohol and propylene glycol (FAPG base) through rat skin: effects of fatty acid added to FAPG base. Chem Pharm Bull 35:2928-2934, 1987.
79. Tojo K. Concentration profile in plasma after transdermal drug delivery. Int J Pharm 43:201-205, 1988.
80. Franz TJ. Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol 64:190-195, 1975.
81. Feldmann RJ, Maibach HI. Absorption of some organic compounds through the skin in man. J Invest Dermatol 54:399-404, 1970.
82. Sheth NV, McKeough MB, Spruance SL. Measurement of stratum corneum drug reservoir to predict the therapeutic efficacy of topical iododeoxyuridine for herpes simplex. J Invest Dermatol 89:598-602, 1987.
83. Ohman H, Vahlquist A. In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis. Acta Derm Venereol (Stockh) 74:375-379, 1994.
84. Erikson G, Lamke L. Regeneration of human epidermal surface and water barrier function after stripping. Acta Derm Venereol (Stockh) 51:169-178, 1971.
85. Wilhelm D, Elsner P, Maibach HI. Standardized trauma (tape-stripping) in human vulvar and forearm skin. Acta Derm Venereol (Stockh) 71:123-126, 1991.
86. Downes AM, Matoltsy AG, Sweeney TM. Rate of turnover of the stratum corneum in hairless mice. J Invest Dermatol 49:400-405, 1967.
87. Pinkus H. Examination of the epidermis by the strip method of removing horny layers. Observations on thickness of the horny layer, and on mitotic activity after stripping. J Invest Dermatol 16:383-386, 1951.
88. Pinkus H. Examination of the epidermis by the strip method of removing horny layers. Biometric data on regeneration of human epidermis. J Invest Dermatol 16:431-447, 1951.
89. Pierard GE, Pierard-Franchimont C, Saint-Leger D, Kligman AM. Squamometry: the assessment of xerosis by colorimetry of D-Squame adhesive discs. J Soc Cosmet Chem 47:297-305, 1992.
90. Schatz H, Kligman AM, Manning S, Stoudemayer T. Quantification of dry (xerotic) skin by image analysis of scales removed by adhesive discs (D-Squame). J Soc Cosmet Chem 44:53-63, 1993.
91. Malkinson FD, Ferguson EH. Percutaneous absorption of hydrocortisone-4-14C in two human subjects. J Invest Dermatol 25:281-285, 1955.
92. Vickers CFH. Existence of reservoir in the stratum corneum. Arch Dermatol 88:2023, 1963.
93. Stoughton RB. Dimethylsulfoxide (DMSO) induction of a steroid reservoir in human skin. Arch Dermatol 91:657-660, 1965.
94. Carr RD, Wieland RG. Corticosteroid reservoir in the stratum corneum. Arch Dermatol 94:81-84, 1966.
95. Carr RD, Tarnowski WM. The corticosteroid reservoir. Arch Dermatol 94:639-642, 1966.
96. Munro DD. The relationship between percutaneous absorption and stratum corneum retention. Br J Dermatol 81(suppl 4):92-97, 1969.
97. Lticker P, Nowak H, Stuttgen G, Werner G. Penetrationskinetik eines Tritium- markierten 9Alpha-fluor-16 methylen-prednisolonesters nach epicutaner Applikation beim Menschen. Arzneimittelforschung 18:27-29, 1968.
98. Tsai J-C, Cappel MJ, Flynn GL, Weiner ND, Kreuter J, Ferry J. Drug and vehicle deposition from topical applications: use of in vitro mass balance technique with minoxidil solutions. J Pharm Sci 81:736-743, 1992.
99. Tojo K, Lee AC. A method for predicting steady-state rate of skin penetration in vivo. J Invest Dermatol 92:105-108, 1989.
100. Moon KC, Wester RC, Maibach HI. Diseased skin models in the hairless guinea pig: in vivo percutaneous absorption. Dermatologica 180:8-121, 1990.
101. Holoyo-Tomoka MT, Kligman AM. Does cellophane tape stripping remove the horny layer? Arch Dermatol 106:767-768, 1972.
102. Malkinson FD. Studies on the percutaneous absorption of14C-labelled steroids by use of glass-flow cell. J Invest Dermatol 31:19-28, 1958.
103. Feldmann RJ, Maibach HI. Penetration of14C hydrocortisone through normal skin: effect of stripping and occlusion. Arch Dermatol 91:661-666, 1965.
104. Zesch A, Schaefer H. Penetrationskinetik von radiomarkierten Hydrocortisone aus verschiedenartigen salbengrundlagen in die Menschliche haut. Arch Dermatol Forsch 252:245-256, 1975.
105. Zesch A, Schaefer H, Hoffmann W. Barriere und reservoirfunktion der einzelnen hornschichtlagen der Menschlichen haut fur lokal aufgetragene Arzneimittel. Arch Dermatol Forsch 246:103-107, 1973.
106. Zesch A. Reservoirfunktion der hornschicht. In: Klaschka F, ed. Stratum corneum: Struktur und Funktion. Berlin: Grosse Verlag, pp 63-76, 1981.
107. Dupuis D, Rougier A, Roguet R, Lotte C. The measurement of the stratum corneum reservoir: a simple method to predict the influence of vehicles on in vivo percutaneous absorption. Br J Dermatol 115:233-238, 1986.
108. Rougier A, Lotte C, Maibach HI. The hairless rat: a relevant animal model to predict in vivo percutaneous absorption in humans? J Invest Dermatol 88:577-581, 1987.
109. Rougier A, Lotte C, Dupuis D. An original predictive method for in vivo percutaneous absorption studies. J Soc Cosmet Chem 38:397-417, 1987.
110. Rougier A, Rallis M, Krien P, Lotte C. In vivo percutaneous absorption: a key role for stratum corneum/vehicle partitioning. Arch Dermatol Res 282:498-505, 1990.
111. Feldmann RJ, Maibach HI. Percutaneous penetration of steroids in man. J Invest Dermatol 52:89-94, 1969.
112. Feldmann RJ, Maibach HI. Percutaneous penetration of some pesticides and herbicides in man. Toxicol Appl Pharmacol 28:126-132, 1974.
113. Auton TR. Skin stripping and science: a mechanistic interpretation using mathematical modelling of skin deposition as a predictor of total absorption. In: Scott RC, Guy RH, Hadgraft J, Bodde HE, eds. Prediction of Percutaneous Penetration. Vol. 2. London: IBC Technical Services, pp 558-576, 1990.
114. Knight AG. The activity of various topical griseofulvin preparations and the appearance of oral griseofulvin in the stratum corneum. Br J Dermatol 91:49-55, 1974.
115. Dittmar W, Jovic N. Laboratory technique alternative to in vivo experiments for studying the liberation, penetration and fungicidal action of topical antimycotic agents in the skin, including ciclopirox olamine. Mykosen 30:326-342, 1986.
116. Pershing LK, Corlett J, Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother 38:90-95, 1994.
117. Pershing LK, Krueger GG. Human skin sandwich flap model for percutaneous absorption. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. New York: Marcel Dekker, pp 397-414, 1989.
118. Parry GE, Dunn P, Shah VP, Pershing LK. Acyclovir bioavailability in human skin. J Invest Dermatol 98:856-863, 1992.
119. Michel C, Purmann T, Mentrup E, Seiller E, Kreuter J. Effect of liposomes on percutaneous penetration of lipophilic materials. Int J Pharm 84:93-105, 1992.
120. Pershing LK, Silver BS, Krueger GG, Shah VP, Skelly JP. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug in skin and a skin blanching bioassay. Pharm Res 9:45-51, 1992.
121. Pershing LK, Lambert LD, Shah VP, Lam SY. Variability and correlation of chro- mameter and tape-stripping methods with the visual skin blanching assay in quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int J Pharm 86:201-210, 1992.
122. Pershing LK, Corlett JL, Lambert LD, Poncelet CE. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo. J Invest Dermatol 102: 734-739, 1994.
123. Pershing LK, Lambert L, Wright ED, Shah VP, Williams RL. Topical 0.05% betamethasone dipropionate: pharmacokinetic and pharmacodynamic dose-response studies in humans. Arch Dermatol 130:740-747, 1994.
124. Tsai JC, Cappel MJ, Weiner ND, Flynn GL, Ferry J. Solvent effects on the harvesting of stratum corneum from hairless mouse skin through adhesive tape stripping in vitro. Int J Pharm 68:127-133, 1991.
125. Tsai JC, Weiner ND, Flynn GL, Ferry J. Properties of adhesive tapes used for stratum corneum stripping. Int J Pharm 72:227-231, 1991.
126. Henn U, Surber C, Schweitzer A, Bieli E. D-Squame adhesive tapes for standardized stratum corneum stripping. In: Brain KR, James VJ, Walters KA, eds. Prediction of Percutaneous Penetration. Vol. 3b. Cardiff: STS Publishing, pp 477-481, 1993.
127. FDA, Center for Drug Evaluation and Research. Draft-Guidance for Industry: Topical Dermatological Drug Product NDAs and ANDAs—In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated Studies. Rockville, MD: Division of Bioequivalence, 1998.
128. Surber C, Schwarb FP, Smith EW. Tape-stripping technique. In: Bronaugh RL, Mai- bach HI, eds. Percutaneous Absorption: Drugs—Cosmetics—Mechanisms—Methodology, 3rd ed. New York: Marcel Dekker, pp 395-409, 1999.
129. Surber C, Wilhelm KP, Hori M, Maibach HI, Guy RH. Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharm Res 7:1320-1324, 1990.
130. Surber C, Wilhelm KP, Berman D, Maibach HI. In vivo skin penetration of acitretin in volunteers using three different sampling techniques. Pharm Res 10:1291-1294, 1993.
131. Laugier J-P, Surber C, Bun H, Geiger J-M, Wilhelm K-P, Durand A, Maibach HI. Determination of acitretin in the skin, in the suction blister, and in plasma of human volunteers after multiple oral dosing. J Pharm Sci 83:623-628, 1994.
132. Fry L, McMinn RMH. Topical methotrexate in psoriasis. Arch Dermatol 96:483-488, 1967.
133. Surber C, Itin P, Buchner S. Clinical controversy on the effect of topical ciclosporin [«'c] A: what is the target organ. Dermatology 185:242-245, 1992.
134. Schaefer H, Lamaud E. Standardization of experimental models. In: Shroot B, Schaefer H, eds. Skin Pharmacokinetics. Basel: Karger, pp 77-80, 1987.
135. Schaefer H, Stuttgen G, Zesch A, Schalla W, Gazith J. Quantitative determination of percutaneous absorption of radiolabeled drugs in vitro and in vivo by human skin. Curr Probl Dermatol 7:80-94, 1978.
136. Wojciechowski Z, Pershing LK, Huether S, Leonard L, Burton SA, Higuchi WI, Krueger GG. An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. J Invest Dermatol 88:439-446, 1987.
137. Wester RC, Noonan PK. Topical bioavailability of a potential anti-acne agent (SC- 23110) as determined by cumulative excretion and areas under plasma concentration time curves. J Invest Dermatol 70:92-94, 1978.
138. Wester RC, Noonan PK, Smeach S, Kosobud L. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. J Pharm Sci 72:745-748, 1983.
139. Wester RC, Maibach HI. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev 14:169-205, 1983.
140. Bucks DAW, McMaster JMA, Maibach HI, Guy RH. Bioavailability of topically administered steroids: a “mass balance” technique. J Invest Dermatol 91:29-33, 1988.
141. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of14C cortisol in man. J Invest Dermatol 48:181-183, 1967.
142. Maibach HI. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 152(suppl 1):11-25, 1976.
143. Wester RC, Maibach HI. Relationship of topical dose and percutaneous absorption in rhesus monkey and man. J Invest Dermatol 67:518-520, 1976.
144. Melendres JL, Bucks DAW, Camel E, Wester RC, Maibach HI. In vivo percutaneous absorption of hydrocortisone: multiple-application dosing in man. Pharmacol Res 9:1164-1167, 1992.
145. Wheeler DA, Moyler DA, Thirkettle JT. Instrumental colour assessment: some practical experience. J Soc Cosmet Chem 27:15-43, 1976.
146. Agache P, Girardot I, Bernengo JC. Optical properties of the skin. In: Leveque JL, ed. Cutaneous Investigation in Health and Disease: Noninvasive Methods and Instrumentation. New York: Marcel Dekker, pp 241-274, 1989.
147. Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. J Invest Dermatol 99:468-473, 1992.
148. el-Gammal S, Hoffmann K, Steiert P, Grassmtiller J, Dirschka T, Altmeyer P. Objective assessment of intra- and inter-individual skin colour variability: an analysis of human skin reaction to sun and UVB. In: Marks R, Plewig G, eds. The Environmental Threat to the Skin. London: Martin Dunitz, pp 99-116, 1992.
149. Seitz JC, Whitemore CG. Measurement of erythema and tanning responses in human skin using a tri-stimulus colorimeter. Dermatologica 177:70-75, 1988.
150. Clarys P, Buchet E, Barel AO. Evaluation of different topical vasodilatory products with non-invasive techniques. In: Scott RC, Guy RH, Hadgraft J, Bodde: HE, eds. Prediction of Percutaneous Penetration. Vol. 2. London: IBC Technical Services, pp 46-59, 1991.
151. Wilhelm K-P, Surber C, Maibach HI. Quantification of sodium lauryl sulfate irritant dermatitis in man: comparison of four techniques: skin color reflectance, transepider- mal water loss, laser Doppler flow measurement and visual scores. Arch Dermatol Res 281:293-295, 1989.
152. Queille-Roussel C, Duteil L, Padilla J-M, Poncet M, Czernielewski J. Objective assessemnt of topical anti-inflammatory drug activity on experimentally induced nickel contact dermatitis: comparison between visual scoring, colorimetry, laser Doppler velocimetry and transepidermal water loss. Skin Pharmacol 3:248-255, 1990.
153. Zhou J, Mark R, Stoudemayer T, Skar A, Lichten JL, Gabriel KL. The value of multiple instrumental and clinical methods, repeated patch applications, and daily evaluations for assessing stratum corneum changes induced by surfactants. J Soc Cosmet Chem 42:105-128, 1991.
154. Lathi A, Kopola H, Harila A, Mullyla A, Hannuksela M. Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chromameter. Arch Dermatol Res 285:278-282, 1993.
155. Treffel P, Gabard B, Bieli E. Relationship between the in vitro diclofenac epidermal level and the in vivo anti-inflammatory efficacy in the methylnicotinate test. In: Brain KR, James VJ, Walters KA, eds. Prediction of Percutaneous Penetration. Vol. 3b. Cardiff: STS Publishing, pp 520-529, 1993.
156. Clarys P, Barel AO, Gabard B. Objective evaluation of the skin blanching induced by corticosteroids. Influence of corticosteroid concentration and body region. In: Brain KR, James VJ, Walters KA, eds. Prediction of Percutaneous Penetration. Vol. 3b. Cardiff: STS Publishing, pp 502-509, 1993.
157. Schwarb FP, Smith EW, Haigh JM, Surber C. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Eur J Pharmacol Biopharmacol 47:261-267, 1999.
158. Demana PH, Smith EW, Walker RB, Haigh JM, Kanfer I. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm Res 14:303-309, 1997.
159. Smith EW, Walker RB, Haigh JM. Analysis of chromameter results obtained from corticosteroid-induced blanching. I. Manipulation of data. Pharm Res 15:280-285, 1998.
160. Troilius A, Wardell K, Bornmyr S, Nilson GE, Ljunggren B. Evaluation of port wine stain perfusion by laser Doppler imaging and thermography before and after argon laser treatment. Acta Derm Venereol (Stockh) 72:6-10, 1992.
161. Quinn AG, McLelland J, Essex T, Farr PM. Quantification of contact allergic inflammation: a comparison of existing methods with a scanning laser Doppler velocimeter. Acta Derm Venereol (Stockh) 73:21-25, 1993.
162. Speight EL, Essex TJH, Farr PM. The study of plaques of psoriasis using a scanning laser Doppler velocimeter. Br J Dermatol 128:519-524, 1993.
163. Guy RH, Tur E, Bugatto B, Gaebel C, Sheiner LB, Maibach HI. Pharmacodynamic measurements of methyl nicotinate percutaneous absorption. Pharm Res 1:76-81, 1984.
164. Poelman MC, Piot B, Guyon M, Leveque JL. Assessment of topical non-steroidal anti-inflammatory drugs. J Pharm Pharmacol 41:720-722, 1989.
165. Hori M, Ohtsuka S, Sunami M, Guy RH, Maibach HI. Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate. Pharm Res 7:1298-1301, 1990.
166. Treffel P, Gabard B. Feasibility of measuring the bioavailability of topical ibuprofen in commercial formulations using drug content in epidermis and methyl nicotinate skin inflammation assay. Skin Pharmacol 129:286-275, 1993.
167. Van Scott EJ. Experimental animal integumental models for screening potential der- matologic drugs. In: Montagna W, Van Scott EJ, Stoughton RB, eds. Pharmacology and the Skin. Advances in Biology of the Skin. New York: Appleton Century Croft, pp 523-533, 1972.
168. Kligman LH, Kligman AM. The effect on rhino mouse skin of agents which influence keratinization and exfoliation. J Invest Dermatol 73:354-358, 1979.
169. Mezick JA, Bhatia MC, Shea LM. Anti-acne activity of retinoids in the rhino mouse. In: Maibach HI, Lowe NJ, eds. Models in Dermatology. Basel: S Karger, pp 59-63, 1985.
170. Bouclier M, Chatelus A, Ferracin J, Delain C, Shroot B, Hensby CN. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standarized image analysis technique. Skin Pharmacol 4:65-73, 1991.
171. Meyer E, Smith EW, Haigh JM. Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. Br J Dermatol 127:379381, 1992.
172. Gilchrest BA, Soter NA, Hawks JLM. Histologic changes associated with ultraviolet- A induced erythema in normal skin. J Am Acad Dermatol 9:213-219, 1983.
173. Woodbury RA, Kligman LH, Woodbury MJ, Kligman AM. Rapid assay of anti-inflammatory activity of topical corticosteroids by inhibition of a UVA-induced neutrophil inflitration in hairless mouse skin. I. The assay and its sensitivity. Acta Derm Venereol (Stockh) 74:15-17, 1994.
174. Kligman LH. Rapid assay of anti-inflammatory activity of topical corticosteroids by inhibition of a UVA-induced neutrophil infiltration in hairless mouse skin. II. Assessment of name brand versus generic potency. Acta Derm Venereol (Stockh) 74:18-19, 1994.
175. Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol 133:31-136, 1977.
176. Consensus Report of the European Task Force on Atopic Dermatits. Severity scoring of atopic dermatitis: the SCORAD Index. Dermatology 186:23-31, 1993.
177. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol 125:235-240, 1989.
178. Berardesca E, Vignoli GP, Farinelli N, Vignini M, Distante F, Rabbiosi G. Non- invasive evaluation of topical calicipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venereol (Stockh) 74:302-304, 1994.
179. Ramsay B, Lawrence AM. Measurement of involved surface area in patients with poriasis. Br J Dermatol 124:565-570, 1991.
180. Larnier C, Ortonne J-P, Venot A, Faivre B, Beani J-C, Thomas P, Brown TC, Sendagorta E. Evaluation of cutaneous photodamage using a photographic scale. Br J Dermatol 130:167-173, 1995.
181. Seitz JC, Spencer TS. Clinical research photography. In: Maibach HI, Lowe NJ, eds. Models in Dermatology. Basel: S Karger, pp 63-70, 1989.
182. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Der- matologica 157:238-244, 1978.
183. Wolska H, Jablonska S, Bounameaux Y. Etretinate in severe psoriasis. Results of a double-blind study and maintenance therapy in pustilar psoriasis. J Am Acad Dermatol 9:883-889, 1983.
184. Geiger J-M, Czarnetzki BM. Acitretin (Ro 10-1670): overall evaluation of clinical studies. Dermatologica 176:182-190, 1988.
185. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi RK. Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 30:977-981, 1994.
186. Kimbrough-Green CK, Griffith CEM, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 130:727-733, 1994.
187. Surber C, Ludin E, Fltickiger A, Dubach UC, Ziegler WH. Pain assessment after intramuscular injection. Arzneimittelforschung 44:1389-1394, 1994.
188. Santos DJ, Juneja M, Bridenbaugh PO. A device for uniform testing of sensory neural blockade during regional anesthesia. Anesth Analg 66:581-582, 1987.
189. Funk JO. Horizons in pharmacologic intervention in allergic contact dermatitis. J Am Acad Dermatol 31:999-1014, 1994.
190. Meingasser JG, Stutz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851-855, 1992.
191. Hannuksela M. Propylene glycol promotes allergic patch test reactions. Boll Dermatol Allergol Prof 2:40-44, 1987.
192. Camarasa JG, Serra-Baldrich E. Allergic contact dermatitis from acyclovir. Contact Dermatitis 19:235-236, 1988.
193. Goh CL. Compound allergy to Spectraban 15 lotion and Zovirax cream. Contact Dermatitis 22:61-62, 1990.
194. Gola M, Francalanci S, Brusi C, Lombardi P, Sertoli A. Contact sensitization to acyclovir. Contact Dermatitis 20:394-395, 1990.
195. Baes H, Van Hecke E. Contact dermatits from Zovirax cream. Contact Dermatits 23: 200-201, 1990.
196. Sidwell RW, Huffman JH, Schafer TW, Shipman C. Influence of vehicle on topical efficacy of 2-acetylpyridine thiosemicarbazone and related derivates on in vivo type 2 herpes simplex virus infections. Chemotherapy 36:58-69, 1990.
197. Weiner N, Williams N, Birch G, Ramachandran C, Shipman C, Flynn G. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother 33:1217-1221, 1989.
198. Imanidis G, Song W, Lee PH, Su MH, Kern ER, Higuchi WI. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice. Pharm Res 11:1035-1041, 1994.
199. Lee PH, Su MH, Kern ER, Higuchi WI. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice. Pharm Res 9:979-989, 1992.
200. Gonsho A, Imanidis G, Vogt P, Kern ER, Tsuge H, Su MH, Choi SH, Higuchi WI. Controlled (trans)dermal delivery of an antiviral agent (acyclovir). I: An in vivo animal model for efficacy evaluation in cutaneous HSV-1 infections. Int J Pharm 65: 183-194, 1990.
201. Lee PH, Su MH, Ghanem AH, Inamori T, Kern ER, Higuchi WI. An application of the C* concept in predicting the topical efficacy of finite dose acyclovir in the treatment of cutaneous HSV-1 infections in hairless mice. Int J Pharm 93:139-152, 1993.
202. Price RW. Neurobiology of human herpes virus infections. Crit Rev Clin Neurobiol 2:61-123, 1986.
203. FDA, Center of Drug Evaluation and Research. Draft guidance for the performance of a bioequivalence study for topical antifungal products. Rockville, MD: Division of Bioequivalence.
204. Aly R, Maibach HI. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox ol- amine cream 1% and clinical efficacy in tinea pedis. Clin Ther 11:290-303, 1989.
205. Eady EA, Cove JH. Topical antibiotic therapy; current status and future prospects. Drugs Exp Clin Res 16:423-433, 1990.
206. Held JL, Kalb RE, Ruszkowski AM, DeLeo V. Allergic contact dermatitis from bacitracin. J Am Acad Dermatol 17:592-594, 1987.
207. Villiger JW, Robertson WD, Kanji K. A comparison of the new topical antibiotic mupirocin (Bactroban) with oral antibiotics in the treatment of skin infections in general practice. Curr Med Res Opin 10:339-345, 1986.
208. Mertz PM, Marshall DA, Eaglestein WH. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 125:1069-1073, 1989.
209. Schwanitz HJ, Macher E. Internal versus topical tetracycline therapy in acne. Z Haut- krankh 59:1515-1521, 1984.
210. Eady EA, Holland KT, Cunliffe WJ. Should topical antibiotics be used for the treatment of acne vulagris? Br J Dermatol 107:235-246, 1982.
211. Buckley MM, Benfiled P. Eutectic lidocaine/prilocaine cream. Drugs 46:126-151, 1993.
212. Foldvari M. In vitro cutaneous and percutaneous delivery and in vivo efficacy of tetracaine from liposomal and conventional vehicles. Pharm Res 11:1593-1598, 1994.
213. Kushla GP, Zatz JL. Evaluation of noninvasive method for monitoring percutaneous absorption of lidocaine in vivo. Pharm Res 7:1033-1037, 1990.
214. Kushla GP, Zatz JL, Mills OH, Berger RS. Noninvasive assessment of anesthetic activity of topical lidocaine formulations. J Pharm Sci 82:1118-1122, 1993.
215. King RB. Topical aspirin in chloroform and the relief of pain due to herpes zoster and postherapeutic neuralgia. Arch Neurol 50:1046-1053, 1993.
216. Brookes FL, Hugo WB, Denyer SP. Transformation of betamethasone-17-valerate by skin microflora. J Pharm Pharmacol 34:61P, 1982.
217. Abu Shamat MS, Beckett AH. Glyceryl trinitrate: metabolism by intestinal flora. J Pharm Pharmacol 35:71P, 1983.
218. Denyer SP, Hugo WB, O’Brien M. Metabolism of glyeryl trinitrate by skin staphylococci. J Pharm Pharmacol 36:61P, 1984.
219. Denyer SP, Guy RH, Hadgraft J, Hugo WB. The microbial degradation of topically applied drugs. Int J Pharm 26:89-97, 1985.
220. Martin RJ, Denyer SP, Hadgraft J. Skin metabolism of topically applied compounds. Int J Pharm 39:23-32, 1987.
221. Shaw JE, Chandrasekaran SK. Controlled topical delivery of drugs for systemic action. Drug Metab Rev 8:223-233, 1978.
222. Samuelov Y, Donbrow M, Friedman M. Effect of pH on salicylic acid permeation through ethyl cellulose-PEG 4000 films. J Pharm Pharmacol 31:120-121, 1979.
223. Jack L, Cameron BD, Scott RC, Hadgraft J. In vitro percutaneous absorption of salicylic acid; effect of vehicle pH. In: Scott RC, Guy RH, Hadgraft J, Bodde HE, eds. Prediction of Percutaneous Penetration. Vol. 2. London: IBC Technical Services, pp 515-518, 1991.
224. Ozer AY, Farivar M, Hincal AA. Temperature- and pH-sensitive liposomes. Eur J Pharm Biopharm 39:97-101, 1993.
225. Tregear RT. Physical Functions of Skin. London: Academic Press, 1966.
226. Wheatley VR. Proc Sci Soc Toilet Goods Assoc 39:25, 1963.
227. Wheatley VR, Flech P, Esoda EGJ, Coon WM, Mandol R. Studies of the chemical composition of the horny layer lipids. J Invest Dermatol 43:395-405, 1964.
228. Wilkenson DI. Variability in composition of surface lipids. J Invest Dermatol 54:339343, 1969.
229. Cheng Y-H, Hosoya O, Sugibayashi K, Morimoto Y. Effect of skin surface lipid on skin permeation of lidocaine from pressure sensitive adhesives. Biol Pharm Bull 17: 1640-1644, 1994.
230. Cummings EG. Temperature and concentration effects on penetration of N-octyamine through human skin in situ. J Invest Dermatol 53:64-70, 1969.
231. Katz M, Poulsen BJ. Absorption of drugs through skin. In: Brodie BB, Gillette JR, eds. Handbook of Experimental Pharmacology, 28. New York: Springer, pp 103-174, 1971.
232. Rothenborg HW, Menne T, Sj0lin KE. Temperature dependent primary irritant dermatitis from lemon perfume. Contact Dermatitis 3:37-48, 1977.
233. Emilson A, Lindberg M, Forslind B. The temperature effect on in vitro penetration of sodium lauryl sulfate and nickel chloride through human skin. Acta Derm Venereol (Stockh) 73:203-207, 1993.
234. James M, Marty J-P, Wepierre J. Diffusion localisee des substances absorbees par voie percutanee. CR Acad Sci (Paris) 278(Ser. D):2063-2066, 1974.
235. James M, Wepierre J. Absorption percutanee de la thyroxine125I et de la triiodothyronine125I chez le rat in vivo. Ann Pharm Fr 32:633-640, 1974.
236. Guy RH, Maibach HI. Drug delivery to local subcutaneous structures following topical administration. J Pharm Sci 72:1375-1380, 1983.
237. Marty J-P, Guy RH, Maibach HI. Percutaneous penetration as a method of delivery to muscle and other tissue. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption: Mechanism—Methodology—Drug Delivery. New York: Marcel Dekker, pp 511-529, 1989.
238. Singh P, Roberts M. Deep tissue penetration of bases and steroids after dermal application in rat. J Pharm Pharmacol 46:956-964, 1994.
239. Benowitz NL, Jacob P, Olsson P, Johansson CJ. Intraveneous nicotine retards trans- dermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption. Clin Pharmacol Ther 52:223-230, 1992.
240. Benowitz NL, Jacob P, Jones RT, Rosenberg J. Interindividual variability in metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221:368-372, 1982.
241. Monteiro-Riviere NA. Altered epidermal morphology secondary to lidocaine iontophoresis: in vivo and in vitro studies in porcine skin. Fundam Appl Toxicol 15:174-185, 1990.
242. Riviere JE, Sage BH, Monteiro-Riviere NA. Transdermal lidocaine ionophoresis in isolated perfused porcine skin. J Toxicol Cutan Ocul Toxicol 8:493-504, 1990.
243. Auclair F, Besnard M, Dupont C, Wepierre J. Importance of blood flow to the local distribution of drugs after percutaneous absorption in the bipediculated dorsal flap of the hairless rat. Skin Pharmacol 4:1-8, 1991.
244. Nakashima E, Noonan PK, Benet LZ. Transdermal bioavailability and first-pass skin matabolism: a preliminary evaluation with nitroglycerin. J Pharmacokinet Biopharm 15:423-437, 1987.
245. Upton RN. Regional pharmacokinetics. I. Physiological and physicochemical basis. Biopharm Drug Dispos 11:647-662, 1990.
246. Turpeinen M, Mashkilleyson N, Bjorksten F, Salo OP. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol (Stockh) 68:331-335, 1988.
247. Turpeinen M. Influence of age and severity of dermatitis on percutaneous absorption of hydrocortisone in children. Br J Dermatol 118:517-522, 1988.
248. Turpeinen M. Absorption of hydrocortisone from the skin reservoir in atopic dermatitis. Br J Dermatol 124:358-360, 1991.
249. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption during and after the acute phase of dermatitis in children. Pediatr Dermatol 5:276-279, 1988.
250. Wester RC, Bucks DAW, Maibach HI. Percutaneous absorption of hydrocortisone in psoriatic patients and normal volunteers. J Am Acad Dermatol 8:645-647, 1983.
251. Wester RC, Mobayen M, Ryatt K, Bucks D, Maibach HI. In vivo percutaneous absorption of dithranol on psoriatic and normal volunteers. In: Farber E, ed. Psoriasis. Amsterdam: Elsevier, pp 429, 1987.
252. Schaefer H, Zesch A, Stuttgen G. Skin Permeability. Berlin: Springer, 1982.
253. Erlanger M, Martz G, Ott F, Storck H, Rider J, Kessler S. Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil following application in an ointment to healthy and diseased human skin. Dermatologica (suppl 1):7-14, 1970.
254. Foreman M, Clanchan I, Kelly I. The diffusion of nandrolone through occluded and non-occluded human skin. J Pharm Pharmacol 30:152-157, 1978.
255. Shani J. Skin penetration of minerals in psoriasis and guinea pig bathing in hypertonic salt solutions. Pharmacol Res Commun 17:501-511, 1985.
256. Wang JCT, Patel BG, Ehmann CW, Lowe N. The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin. J Am Acad Dermatol 16:812-821, 1987.
257. Juhlin L, Hagglund G, Evers H. Absorption of lidocaine and prilocaine after application of eutectic mixture of local anesthetics (EMLA) on normal and diseased skin. Acta Derm Venereol (Stockh) 69:18-22, 1989.
258. Maibach HI, Feldmann RJ, Milby TH, Serat WF. Regional variation in percutaneous penetration in man. Arch Environ Health 23:208-211, 1971.
259. Elias PM, Cooper ER, Korc A, Brown BE. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol 76:297-301, 1981.
260. Scott RC, Corrigan MA, Smith F, Mason H. The influence of skin structure on permeability: an intersite and interspecies comparison with hydrophilic penetrants. J Invest Dermatol 96:921-925, 1991.
261. Ebihara A, Fujimura A, Ohashi K, Shiga T, Kumagai Y, Nakashima H, Kotegawa T. Influence of application site of a new transdermal clonidine, M-5041T, on its phar- makokinetics and pharmacodynamics in healthy subjects. J Clin Pharmacol 33:11881191, 1993.
262. Hopkins K, Aarons L, Rowland M. Absorption of clonidine from transdermal therapeutic system when applied to different body sites. In: Weber MA, Mathias CJ, eds. Mild Hypertension. Darmstadt: Steinkopf. pp 143-147, 1984.
263. Hansen MS, Woods SL, Willis RE. Relative effectiveness of nitroglycerin ointment according to site of application. Heart Lung 8:716-720, 1979.
264. Moe G, Armstrong PW. Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. Am J Med 81:765-770, 1986.
265. Noonan PK, Wester RC. Percutaneous absorption of nitroglycerin. J Pharm Sci 69: 385-386, 1980.
266. Shah AK, Wei G, Lamman RC, Bhargava VO, Weir SJ. Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm Res 13:168-172, 1996.
267. Stoughton RB. Percutaneous absorption of drugs. Annu Rev Pharmacol Toxicol 29: 55-69, 1989.
268. Scheuplein RJ. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J Invest Dermatol 48:7988, 1967.
269. Albery WJ, Hadgraft J. Percutaneous absorption: in vivo experiments. J Pharm Pharmacol 31:140-147, 1979.
270. Pratzel HG. Iontophorese. Berlin: Springer, 1987.
271. Mackee GM, Sulzberger MB, Herrmann F, Bare RL. Histologic studies on percutaneous penetration with special reference to the effects of vehicles. J Invest Dermatol 6:43-61, 1945.
272. Tregear RT. Relative penetrability of hair follicles and epidermis. J Physiol 156:307-313, 1961.
273. Grasso P. Some aspects of the role of skin appendages in percutaneous absorption. J Soc Cosmet Chem 22:523-534, 1971.
274. Schaefer H, Watts F, Brod J, Illel B. Follicular penetration. In: Scott RC, Guy RH, Hadgraft J, eds. Prediction of Percutaneous Penetration. Vol. 1. London: IBC Technical Services, pp 163-173, 1990.
275. Lauer AC, Lieb LM, Ramachandran C, Flynn GL, Weiner ND. Transfollicular drug delivery. Pharm Res 12:179-186, 1995.
276. Scheuplein RJ. Mechanism of percutaneous absorption. J Invest Dermatol 45:334346, 1965.
277. Scheuplein RJ, Blank IH, Brauner GJ, MacFarlane DJ. Percutaneous absorption of steroids. J Invest Dermatol 52:63-70, 1969.
278. Shelly WB, Melton FM. Studies on absorption through normal human skin. FASEB 6:199-200, 1947.
279. Behl CR, Bellantone NH, Flynn GL. Influence of age on percutaneous absorption of drug substances. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption: Mech- anism—Methodology—Drug Delivery. New York: Marcel Dekker, pp 183-212, 1985.
280. Suzuki M, Asaba K, Komatsu H, Mochizuka M. Autoradiographic study on percutaneous absorption of several oils useful for cosmetics. J Soc Cosmet Chem 29:265-282, 1978.
281. Nicolau G, Baughman RA, Tonelli A, McWilliams W, Schiltz J, Yacobi A. Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals. Xenobiotica 17:1113-1120, 1987.
282. Borelli, Metzger M. Fluorescenzmikroskopische untersuchungen uber die perkutane penetration fluorescierender stoffe. Hautarzt 8:261-266, 1957.
283. Kao J, Hall J, Helman G. In vitro percutaneous absorption in mouse skin: influence of skin appendages. Toxicol Appl Pharmacol 94:93-103, 1988.
284. Wallace SM, Barnett G. Pharmacokinetic analysis of percutaneous absorption: evidence of parallel penetration pathways for methotrexate. J Pharmacokinet Biopharm 6:315-325, 1978.
285. Keister JC, Kasting GB. The use of transient diffusion to investigate transport pathways through skin. J Control Release 4:111-117, 1986.
286. Corroller M, Didry JR, Siou G, Wepierre J. Sebaceous accumulation of linoleic acid following topical application in the hairless rat its mathematical treatment. In: Shroot B, Schaefer H, eds. Skin Pharmacokinetics. Basel: Karger, pp 111-120, 1987.
287. Illel B, Schaefer H, Wepierre J, Doucet O. Follicles play an important role in percutaneous absorption. J Pharm Sci 80:424-427, 1991.
288. Illel B, Schaefer H. Transfollicular percutaneous absorption. Acta Derm Venereol (Stockh) 68:427-457, 1988.
289. Behl CR, Wittkowsky A, Barett M, Pierson CL, Flynn GL. Technique for preparing appendage-free skin (scar) on hairless mouse. J Pharm Sci 70:835-837, 1981.
290. Hueber F, Schaefer H, Wepierre J. Role of transepidermal and transfollicular routes in percutaneous absorption of steroids: in vitro studies on human skin. Skin Pharmacol 7:237-244, 1994.
291. Hueber F, Besnard M, Schaefer H, Wepierre J. Percutaneous absorption of estradiol and progesterone in normal and appendage-free skin of the hairless rat: lack of importance of nutritional blood flow. Skin Pharmacol 7:245-256, 1994.
292. Hueber F, Wepierre J, Schaefer H. Role of transepidermal and transfollicular routes in percutaneous absorption of hydrocortisone and testosterone: in vivo study on hairless rat. Skin Pharmacol 5:99-107, 1992.
293. Mukherji E, Millenbaugh NJ, Au J. Percutaneous absorption of 2',3'-dideoxyinosine in rats. Pharm Res 11:809-815, 1994.
294. Bamba FL, Wepierre J. Role of appendageal pathway in the percutaneous absorption of pyridostigmine bromide in various vehicles. Eur J Drug Metab Pharmacokinet 18: 339-348, 1993.
295. Tur E, Maibach HI, Guy RI. Percutaneous penetration of methyl nicotinate at three anatomic sites: evidence for appendageal contribution to transport? Skin Pharmacol 4:230-234, 1991.
296. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 10:1738-1744, 1993.
297. Chan SY, Po ALW. Prodrugs for dermal delivery. Int J Pharm 55:1-16, 1989.
298. Kao J, Carver MP. Cutaneous metabolism of xenobiotics. Drug Metab Rev 22:363410, 1990.
299. Loden M. The in vitro hydrolysis of di-isopropyl fluorophosphate during penetration through human full-thickness skin and isolated epidermis. J Invest Dermatol 85:335-339, 1985.
300. Potts RO, Guy RH. A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm Res 12:1628-1633, 1995.
301. Hadgraft J. Theoretical aspects of metabolism in the epidermis. Int J Pharm 4:229-239, 1980.
302. Guy RH, Hadgraft J, Maibach HI. A pharmacokinetic model for percutaneous absorption. Int J Pharm 11:119-129, 1982.
303. Tojo K, Valia KH, Chotani G, Chien YW. Long-term permeation kinetics of estradiol: (IV) a theroretical approach to the simultaneous skin permeation and bioconversion of estradiol. Drug Dev Ind Pharm 11:1175-1193, 1985.
304. Potts RO, McNeill SC, Desbonnet CR, Wakshull E. Transdermal drug transport and metabolism: II. The role of competing kinetic events. Pharm Res 6:119-124, 1989.
305. Sloan KB. Prodrugs: Topical and Ocular Drug Delivery. New York: Marcel Dekker, 1992.
306. Bodor, N., Kaminski, J.J., Selk, S., Softdrugs, I. Labile quaternary ammonium salts as soft antibacterials. J Med Chem 23:469-474, 1980.
307. Roskos KV, Maibach HI, Guy RH. The effect of aging on percutaneous absorption in man. J Pharmacokinet Biopharm 17:617-630, 1989.
308. Harvell JD, Maibach HI. Percutaneous absorption and inflammation in aged skin: a review. J Am Acad Dermatol 31:1015-1021, 1994.
309. Micalis S, Bhatt RH, Distefano S, Caltabiano L, Cook B, Fischer J, Solomon LM, West DP. Evaluation of transdermal theophylline pharmacokinetics in neonates. Pharmacotherapy 13:386-390, 1993.
310. Barrett DA, Rutter N. Transdermal delivery and the premature neonate. Crit Rev Ther Drug Carrier Syst 11:1-30, 1994.
311. Weigand DA, Gaylor JR. Irritant reaction in Negro and Caucasian skin. South Med J 67:548-551, 1974.
312. Johnson LC, Corah NL. Racial differences in skin resistance. Science 139:766-767, 1960.
313. Reinertson RP, Wheatley VR. Studies on the chemical composition of human epidermal lipids. J Invest Dermatol 32:49-59, 1959.
314. Berardesca E, Maibach HI. Racial differences in sodium lauryl sulphate induced cutaneous irritation: black and white. Contact Dermatitis 17:12-17, 1987.
315. Williams RL, Thakker KM, John V, Lin ET, Gee WL, Benet LZ. Nitroglycerin absorption from transdermal systems: formulation effects and metabolic concentrations. Pharm Res 8:744-749, 1991.
316. Levy G. The clay feet of bioequivalence testing. J Pharm Pharmacol 47:975-977, 1995.
317. Hauck WW, Anderson S. Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm 22:551-564, 1994.
318. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 121:63-67, 1985.
319. Ferreira LAM, Seiller M, Grossiord JL, Marty JP, Wepierre J. Vehicle influence on in vitro release and percutaneous absorption of glucose: role of W/O/W multiple emulsion. Proc Int Symp Control Release Bioact Mater 21:453-454, 1994.
320. Ferreira LAM, Doucet J, Seiller M, Grossiord JL, Marty JP, Wepierre J. In vitro percutaneous absorption of metronidazole and glucose: comparison of O/W, W/O/W and W/O systems. Int J Pharm 121:169-179, 1995.
321. Friedman DI, Schwarz JS, Weisspapir M. Sub-micron emulsion vehicle for enhanced transdermal delivery of steroidal antiinflammatory drugs. J Pharm Sci 84:324-329, 1995.
322. Kondo S, Yamanaka C, Sugimoto I. Enhancement of transdermal delivery by superfluous thermodynamic potential. III. Percutaneous absorption of nifedipine in rats. J Pharmacobiodyn 10:743-749, 1987.
323. Megrab NA, Williams AC, Barry BW. Oestradiol permeation through human skin and Silastic membrane: effects of propylene glycol and supersaturation. J Control Release 36:277-294, 1995.
324. Sato K, Sugibayashi K, Morimoto Y. Effect of mode of action of aliphatic esters on the in-vitro skin penetration of nicorandil. Int J Pharm 43:31-40, 1988.
325. Yamane MA, Williams AC, Barry BW. Effects of terpenes and oleic acid as skin penetration enhancers towards 5-fluorouracil as assessed with time; permeation, partitioning and differential scanning calorimetry. Int J Pharm 116:237-251, 1995.
326. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11:85-97, 1960.
327. Reifenrath WG, Hawkins GS, Kurtz MS. Percutaneous penetration and skin retention of topically applied compounds: an in vitro-in vivo study. J Pharm Sci 80:526-532, 1991.
328. Surber C, Wilhelm K-P, Maibach HI. In vitro skin pharmacokinetics of acitretin: percutaneous absorption studies in intact and modified skin of three different species. J Pharm Pharmacol 43:836-840, 1991.
329. Elias PM. Epidermal lipids, membranes, and keratinization. Int J Dermatol 2:1-19, 1981.
330. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 9:663-669, 1992.
331. Pugh WJ, Roberts MS, Hadgraft J, Degim T. Relationship between H-bonding of penetrants to stratum corneum lipids and diffusion within the stratum corneum. In: Brain KR, James VJ, Walters KA, eds. Prediction of Percutaneous Penetration. Vol. 4b. Cardiff: STS Publishing, pp 48-51, 1996.
332. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 123:1312-1314, 1987.
333. Poulsen BJ, Young E, Coquilla V, Katz M. Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester. J Pharm Sci 57: 928-933, 1968.
334. Ostrenga J, Steinmetz C, Poulsen B. Significance of vehicle composition I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 60:1175-1179, 1971.
335. Twist JN, Zatz JL. Influence of solvents on paraben permeation through idealized skin model membranes. J Soc Cosmet Chem 37:429-444, 1986.
336. Yalkowsky SH, Valvani SC, Amidon GL. Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci 65:1488-1494, 1976.
337. Hadgraft J, Hadgraft JW, Sarkany I. The effect of glycerol on percutaneous absorption of methyl nicotinate. Br J Dermatol 87:30-36, 1972.
338. Lippold BC, Schneemann H. The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution and suspension-type ointments. Int J Pharm 22:31-43, 1984.
339. Dugard PH, Scott RC. A method of predicting percutaneous absorption rates from vehicle to vehicle: an experimental assessment. Int J Pharm 28:219-227, 1986.
340. Goodman M, Barry BW. Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique. Int J Pharm 57:29-40, 1989.
341. Lamaud E, Schalla W, Schafer H. Effect of repeated rubbing on the in vivo penetration of hydrocortisone. In: Schafer H, Schalla W, Shroot B, eds. Advances in Skin Pharmacology and Skin Pharmacokinetics; Nice: Centre International de Recherche Der- matologiques. pp 23-24, 1986.
342. McMaster J, Maibach HI, Wester RC, Bucks DAW. Does rubbing enhance in vivo dermal absorption? In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption: Mechanism—Methodoloy—Drug Delivery. New York: Marcel Dekker, pp 359-361, 1985.
343. Idson B. Percutaneous absorption. J Pharm Sci 64:901-924, 1975.
344. Garb J. Nevus verrucosus unilateris cured with podophyllin ointment. Arch Dermatol 81:606-609, 1960.
345. Scholtz JR. Topical therapy of psoriasis with fluocinolone acetonide. Arch Dermatol 84:1029-1030, 1961.
346. Sulzberger MB, Witten VH. Thin pliable plastic films in topical dermatologic therapy. Arch Dermatol 84:1027-1028, 1961.
347. McKenzie AW. Percutaneous absorption of steroids. Arch Dermatol 86:91-94, 1962.
348. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 86:608-610, 1962.
349. Guy RH, Bucks DAW, McMaster JR, Villaflor DA, Roskos KV, Hinz RS, Maibach HI. Kinetics of drug absorption across human skin in vivo: developments in methodology. Skin Pharmacol 1:70-76, 1988.
350. Kim HO, Wester RC, McMaster JA, Bucks DAW, Maibach HI. Skin absorption from patch test systems. Contact Dermatitis 17:178-180, 1987.
351. Auton TR, Westhead DR, Woollen BH, Scott RC, Wilks MF. A physiologically based mathematical model of dermal absorption in man. Hum Exp Toxicol 13:51-60, 1994.
352. Johnson R, Nusbaum BP, Horwitz SN, Frost P. Transfer of topically applied tetracycline in various vehicles. Arch Dermatol 119:660-663, 1983.
353. Haupenthal H, Heilmann P, Moll F. Kuhlsalben. Krankenhauspharm 15:671-674, 1994.
354. Reifenrath WG, Robinson PB. In vitro skin evaporation and penetration characteristics of mosquito repellents. J Pharm Sci 71:1014-1018, 1982.
355. Hawkins GS, Reifenrath WG. Influence of skin source, penetration cell fluid, and partition coefficient on in vitro skin penetration. J Pharm Sci 75:378-381, 1986.
356. Reifenrath WG, Spencer TS. Evaporation and penetration from skin. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption: Mechanism—Methodolgy—Drug Delivery. New York: Marcel Dekker, pp 313-334, 1989.
357. Coldman MF, Poulsen BJ, Higuchi T. Enhancement of percutaneous absorption by the use of volatile:nonvolatile systems as vehicles. J Pharm Sci 58:1098-1102, 1969.
358. Chiang C-M, Flynn GL, Weiner ND, Szpunar GJ. Bioavailability assessment of topical delivery systems: effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations. Int J Pharm 55:229-236, 1989.
359. Kemken J, Ziegler A, Muller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res 9:554-558, 1992.
360. de Carvalho M, Falson-Rieg F, Eynard I, Rojas J, Lafforgue C, Hadgraft J. Changes in vehicle composition during skin permeation studies. In: Brain KR, James VJ, Walters KA, eds. Prediction of Percutaneous Penetration. Vol. 3b. Cardiff: STS Publishing, pp 251-254, 1993.
361. Guy RH, Hadgraft J. Percutaneous absorption kinetics of topically applied agents liable to surface loss. J Soc Cosmet Chem 35:103-113, 1984.
362. Flynn GL. Topical drug absorption and topical pharmaceutical systems. In: Banker GS, Rhodes CT, eds. Modern Pharmaceutics. New York: Marcel Dekker, pp 263-325, 1990.
363. Williams PL, Brooks JD, Inman AO, Monteiro-Riviere NA, Riviere JE. Determination of physicochemical properties of phenol, p-nitrophenol, acetone and ethanol relevant to quantitating their percutaneous absorption in porcine skin. Res Commun Chem Pathol Pharmacol 83:61-75, 1994.
364. Polano MK. Topical Skin Therapeutics. Edinburgh: Churchill Livingstone, 1984.
365. Schlagel CA, Sanborn EC. The weights of topical preparations required for total and partial body inuction. J Invest Dermatol 42:253-256, 1964.
366. Griffiths WAD, Wilkinson JD. Topical therapy. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL, eds. Textbook of Dermatology. London: Blackwell Scientific, pp 3037-3084, 1992.
367. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. St. Louis: CV Mosby, 1990.
368. Long CC. The rule of hand: 4 hand areas = 2 FTU 1 g. Arch Dermatol 128:1129-1130, 1992.
369. Lutz UL, Weirich E. Untersuchungen zur hautflachen-Dosis von Dermatopharma- kotherapeutika. Z Hautkr 50:753-769, 1975.
370. Willis I, Kligman AM. Evaluation of sunscreen by human assay. J Soc Cosmet Chem 20:639-651, 1969.
371. Lynfield YL, Schechter S. Choosing and using a vehicle. J Am Acad Dermatol 10: 59, 1984.
372. Kaidberg KH, Kligman AM. Laboratory methods for appraising the efficacy of sunscreens. J Soc Cosmet Chem 29:525-536, 1978.
373. FDA. Sunscreen drug products for over-the counter human use. Fed Reg 43:38206-38269, 1978.
374. Bech-Thomsen N, Wulff HC. Sunbather’s application of sunscreen is probably inadequate to obtain the sun protection factor assigned to the preparation. Photodermatol Photoimmunol Photomed 9:242-244, 1993.
375. Loesch H, Kaplan DL. Pitfalls in sunscreen application. Arch Dermatol 130:665-666, 1994.
376. Shah VP, Behl CR, Flynn GL, Higuchi WI, Schaefer H. Principles and criteria in the development and optimization of topical therapeutic products. J Pharm Sci 81:1051-1054, 1992.
377. Ferry JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied dose and percutaneous absorption of minoxidil from topical solution. J Pharm Sci 79:483-486, 1990.
378. Tauber U, Matthes H. Percutaneous absorption of methylprednisolone aceponate after single and multiple dermal application as ointment in male volunteers. Arzneimittelf- forschung 42:1122-1124, 1992.
379. Gao HY, Li Wan Po A. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur J Clin Pharmacol 46:71-75, 1994.
380. Wester RC, Melendres J, Sedik L, Maibach HI. Percutaneous absorption of Azone following single and multiple doses to human volunteers. J Pharm Sci 83:124-125, 1994.
381. Carslaw HS, Jaeger JC. Conduction of Heat in Solids. London: Oxford University Press, 1959.
382. Franz TJ. Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol 64:190-195, 1975.
383. Franz TJ. The finite dose techniques as a valid in vitro model for the study of percutaneous absorption in man. Curr Probl Dermatol 7:58-68, 1978.
384. Fox JL, Yu C-D, Higuchi WI, Ho NFH. General physical model for simultaneous diffusion and metabolism in biological membranes. The computational approach for the steady-state case. Int J Pharmaceut 2:41-57, 1979.
385. Okamoto H, Yamashita F, Saito K, Hashida M. Analysis of drug penetration through the skin by two-layer skin model. Pharm Res 6:931-937, 1989.
386. Addicks WJ, Flynn GL, Weiner N, Curl RA. A mathematical model to describe drug release from thin topical application. Int J Pharm 56:243-248, 1989.
387. Kubota K, Yamada T. Finite dose percutaneous absorption: theory and its application to in vitro timolol permeation. J Pharm Sci 79:1015-1019, 1990.
388. Kubota K. Finite dose percutaneous drug absorption: a BASIC program for the solution of the diffusion equation. Comput Biomed Res 24:196-207, 1991.
389. Seta Y, Ghanem AH, Higuchi WI, Borsadia S, Behl CR, Malick AW. Physical model approach to understanding finite dose transport and uptake of hydrocortisone in hairless guinea pig skin. Int J Pharm 81:89-99, 1992.
390. Malkinson FD, Ferguson EH. Percutaneous absorption of hydrocortisone-4-C14 in two subjects. J Invest Dermatol 25:281-283, 1956.
391. Feldmann RJ, Maibach HI. Percutaneous penetration of hydrocortisone with urea. Arch Dermatol 109:58-59, 1974.
392. Britz MB, Maibach HI, Anjo DM. Human percutaneous absorption of hydrocortisone: the vulva. Arch Dermatol Res 267:313-316, 1980.
393. Bucks DAW, Maibach HI, Guy RH. Percutaneous absortion of steroids: effect of repeated application. J Pharm Sci 74:1337-1339, 1985.
394. Maibach HI, Feldmann RJ. Percutaneous penetration in man: comparison of some steroids. Clin Res 14:270, 1966.
395. Franz TJ, Lehman PA. Percutaneous absorption of fluocinolone in man: assessment of relative bioequivalence of 0.05% Lidex ointment and solution. Pharm Res 7(suppl 194):PDD 7331, 1990.
396. Wickrema SAJ, Shaw SR, Weber DJ. Percutaneous absorption and excretion of tritium-labeled diflorasone diacetate, a new topical corticosteroid in the rat, monkey and man. J Invest Dermatol 71:372-377, 1978.
397. Bucks DAW, Maibach HI, Guy RH. Mass balance and dose accountability in percutaneous absorption studies: development of a nonocclusive application system. Pharm Res 5:313-314, 1988.
398. Stoughton RB, Wullich K. Relation of application time to bioactivity of a potent topical glucocorticosteroid formulation. J Am Acad Dermatol 22:1038-1041, 1990.
399. Maibach HI, Feldmann R. Effect of applied concentration on percutaneous absorption in man. J Invest Dermatol 52:382, 1969.
400. Roberts MS, Horlock E. Effect of repeated skin application on percutaneous absorption of salicylic acid. J Pharm Sci 67:1685-1687, 1978.
401. Lippold BC, Reimann H. Wirkungsbeeinflussung bei losungssalben durch Vehikel am beispiel von Methylnicotinat. Acta Pharm Technol 35:128-135, 1989.
402. Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Arch Dermatol 125:1509-1511, 1989.
403. Guin JD, Wallis MS, Wall MS, Lehmann PA, Franz TJ. Quantitative vasoconstrictor assay for topical corticosteroids: the puzzling case of fluocinolone acetonide. J Am Acad Dermatol 29:197-202, 1993.
404. Gibson JR, Hough JE, Marks PM. Effect of concentration on the clinical pharmacology of corticosteroid ointment formulations. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel: S Karger, pp 74-92, 1992.
405. Gibson JR, Kirsch J, Darley CR, Burke CA. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations. Clin Exp Dermatol 8:489-493, 1983.
406. Walker M, Chambers LA, Hollingsbee DA, Hadgraft J. Significance of vehicle thickness to skin penetration of halcinonide. Int J Pharm 70:167-172, 1991.
407. Jackson DB, Thompson C, McCormack JR, Guin JD. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol 20:791-796, 1989.
408. Barry BW, Woodford R. Comparative bioavailability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol 91:323-338, 1974.
409. Magnus AD, Haigh JM, Kanfer I. Assessment of some variables affecting the blanching activity of betamethasone-17-valerate cream. Dermatologica 160:321-327, 1980.
410. Zesch A. Zur Bioaquivalenz und Bioverftigbarkeit topisch applizierter Arzneimittel. Pharm Ind 50:746-749, 1988.
411. Treffel P, Gabard B. Ibuprofen epidermal levels after topical application in vitro: effect of formulation, application time, dose variation and occlusion. Br J Dermatol 127: 286-291, 1993.
412. Claris P. Non-invasive Biophysical Measurements on the Skin: The Use of Some Bioengineering Methods for the Assessment of Percutaneous Penetration. Brussels: Vrije Universiteit Brussel; 1994.
413. Unna PG. Cigolin als heilmittel der Psoriasis. Dermatol Wochenschr 6:116-137; 150-163; 175-183, 1916.
414. Farber FM, Harris DR. Hospital treatment of psoriasis. A modified anthralin therapy. Arch Dermatol 101:381-389, 1970.
415. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithra- nol in psoriasis. Br J Dermatol 102:571-573, 1980.
416. Schalla W, Bauer E, Wesendahl C, Goldberg L, Farber EM, Schaefer H. Arch Dermatol Res 267:203, 1980.
417. Runne U, Kunze J. Short-duration (“minutes”) therapy with dithranol for psoriasis: a new out-patient regimen. Br J Dermatol 106:135-139, 1982.
418. Schaefer H, Schalla W, Shroot B. Anthralin—facts, trends and unresolved problems. In: Hornstein OP, Schnyder UW, Schonfeld J, eds. Neue Entwicklungen in der Der- matologie. Berlin: Springer, pp 82-91, 1984.
419. Jaeger L. Psoriasis treatment with betamethasone dipropionate using short-term application and short-term occlusion. Acta Derm Venereol (Stockh) 66:84-87, 1986.
420. Leibsohn E. Comparison of diflorasone diacetate and betamethasone dipropionate ointment in the treatment of psoriasis. J Int Med Res 10:22-27, 1982.
421. Taplin D, Rivera A, Walker JG, Roth WI, Reno D, Meinking T. A comparative trial of three treatment schedules for the eradication of scabies. J Am Acad Dermatol 9: 554, 1983.
422. Wester RC, Noonan PK, Maibach HI. Frequency of application on percutaneous absorption of hydrocortisone. Arch Dermatol 113:620-622, 1977.
423. Wester RC, Noonan PK, Maibach HI. Percutaneous absorption of hydrocortisone increases with long-term administration. Arch Dermatol 116:186-188, 1980.
424. Tauber U. Skin pharmacokinetics of the new topical glucocorticosteroid MPA. In: Scott RC, Guy RH, Hadgraft J, eds. Prediction of Percutaneous Penetration. Vol. 1. London: IBC Technical Services, pp 37-48, 1990.
425. Tauber U, Weiss C, Matthes H. Does salicylic acid increase the percutaneous absorption of diflucortolone-21-valerate. Skin Pharmacol 6:276-281, 1993.
426. Tsai JC, Flynn GL, Weiner N, Ferry JJ. Influence of application time and formulation reapplication on the delivery of minoxidil through hairless mouse skin as measured in Franz diffusion cells. Skin Pharmacol 7:270-277, 1994.
427. Sherertz EF, Sloan KB, McTiernan RG. Effect of skin pretreatment with vehicle alone or drug in vehicle on flux of a subsequently applied drug: results of hairless mouse skin and diffusion cell studies. J Invest Dermatol 89:249-252, 1987.
428. Fredriksson T, Lassus A, Bleeker J. Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily. Br J Dermatol 102:575-577, 1980.
429. Sudilovsky A, Muir JG, Bococo FC. A comparison of single and multiple applications of halcinonide cream. Int J Dermatol 20:609-613, 1981.
430. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 25:665-667, 1991.
431. Frosch PJ, Behrenbeck EM, Frosch K, Macher E. The Duhring chamber assay for corticosteroid atrophy. Br J Dermatol 104:57-65, 1981.
432. Lehmann P, Zheng P, Lavker RM, Kligman A. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 81:169-176, 1983.
433. Lavker RM, Schechter NM, Lazarus GS. Effects of topical corticosteroids on human dermis. Br J Dermatol 115(suppl 31):101-107, 1986.
434. Woodbury R, Kligman AM. The hairless mouse model for assaying the atrophogen- icity of topical corticosteroids. Acta Derm Venereol (Stockh) 72:403-406, 1989.
435. Lubach D, Kietzmann M. Anti-inflammatory effect and thinning of the skin: models for testing topically applied corticosteroids on human skin. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel: S Karger, pp 26-41, 1992.
436. Pflugshaupt C. Diskontinuierliche topische Kortikoidtherapie. Zbl Haut Geschlecht- skrankh 148:1229-1367, 1983.
437. English JS, Bunker CB, Ruthven K, Dowd PM, Greaves MW. A double-blind comparison of efficacy of betamethasone dipropionate cream twice daily versus once daily in the treatment of steroid responsive dermatoses. Clin Exp Dermatol 14:32-34, 1989.
438. Lubach D, Rath J, Kietzmann M. Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. Dermatology 185:44-48, 1992.
439. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Dermato- logica 179:67-72, 1989.
440. Wozel G, Barth J. Fluocinolonacetonid und Psoriasis—kontinuierliche und alterni- erende Therapie. Dermatol Monatsschr 172:620-623, 1986.
441. Lubach D, Rath J, Kietzmann M. Alteration of skin thickness induced by initial continuous followed by intermittent topical application of clobetasol. Dermatology 190: 51-55, 1995.
442. Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM. Betamethasone dipropionate in optimized vehicle: intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 123:1308-1311, 1987.
443. Levy G. Bioavailability, clinical effectiveness, and public interest. Pharmacology 8: 33-43, 1972.
444. Shah VP, Van Zwieten-Boot B. Characterisation of topical products for local action —quality, efficacy and safety. Symposium on Quality and Interchangeability of Topical Products for Local Action, Dec 8; Niirnberg: European Federation for Pharmaceutical Sciences, 1995.
445. Yacobi A, Skelly JP, Shah V, Benet LZ. Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. New York: Plenum Press, 1993.
446. Peck CC, Collins JM. First time in man studies; a regulatory perspective—art and science of phase I trials. J Clin Pharmacol 30:218-222, 1990.
447. Narang PK, Bianchine JR. Phase I studies: initial evaluation of drug toxicity, dose response, and efficacy. In: Max M, Portenoy R, Laska E, eds. Advances in Pain Research and Therapy: 18, New York: Raven Press, pp 9-31, 1991.
448. Levy G. Concentration-controlled versus concentration-defined clinical trials. Clin Pharmacol Ther 53:387-388, 1993.
449. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 56:1-8, 1994.
450. Urquart J. How much compliance is enough? Pharm Res 13:10-11, 1996.
451. Meyer UA, Kindli R. Plazebos und nozebos. Ther Umsch 46:544-554, 1989.
452. Pearce JMS. The placebo enigma. Q J Med 88:215-220, 1995.
453. Ernst E, Resch KL. Concept of true and perceived placebo effects. Br Med J 311: 551-553, 1995.
454. Golomb BA. Paradox of placebo effect. Nature 375:530, 1995.
455. Olson SC, Eldon MA, Toothaker RD, Ferry JJ, Colburn WA. Controversy. II: bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect. J Clin Pharmacol 27:342-345, 1987.
456. Lee JW, Hulse JD, Colburn WA. Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol 35:464-470, 1995.
457. Barrett CW, Hadgraft JW. The effect of particle size and the vehicle on the percutaneous absorption of fluocinolone acetonide. Br J Dermatol 77:576-578, 1965.
458. Sarkany I, Hadgraft JW, Caron GA, Barrett CW. The role of vehicles in the percutaneous absorption of corticosteroids. Br J Dermatol 77:569-575, 1965.
459. Christie GA, Moore-Robinson M. Vehicle assessment—methodology and results. Br J Dermatol 82(suppl. 6):93-98, 1970.
460. Barry BW. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments. Br J Dermatol 93: 563-567, 1975.
461. Barry BW. Proprietary hydrocortisone creams, vasoconstrictor activities and bio-availabilities of six preparations. Br J Dermatol 95:423-425, 1976.
462. Barry BW, Woodford R. Vasoconstrictor activities and bioavailabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications. Br J Dermatol 97:555-560, 1977.
463. Woodford R, Barry BW. Activity and bioavailability of amcinolone and triamcinolone acetonide in experimental and proprietary topical preparations. Curr Ther Res 21: 877-886, 1977.
464. Stoughton RB, Cornell RC. Review of super-potent topical corticosteroids. Semin Dermatol 6:72-76, 1987.
465. Shah VP, Peck CC, Skelly JP. “Vasoconstriction”—skin blanching-assay for gluco- corticosteroids—a critique. Arch Dermatol 125:1558-1561, 1989.
466. Olsen E. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 127:197-201, 1991.
467. Agrawal N, Lehman PA, Franz TJ. Bioavailability of hydrocortisone from seven topical formulations using the in vitro finite dose method. Pharm Res 12:S-277, 1995.
468. Lehman PA, Franz TJ. Bioavailability of hydroquinone from six topical formulations using the in vitro finite dose method. Pharm Res 9:S-233, 1992.
469. Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 16:917-923, 1999.
470. Marks R, Dykes PJ, Gordon J, Halan G, Davis A. Percutaneous penetration from a low dose supersaturated hydrocortisone acetate formulation. Presented at the British Society of Investigative Dermatology Annual Meeting, Sheffield, 1992.
471. Sanathanan LP, Peck CC, Temple RT, Lieberman R, Pledger G. Randomization, PK- controlled dosing, and titration: an integrated approach for designing clinical trials. Drug Inform J 25:425-431, 1991.
472. Levy G. Patient-oriented pharmaceutical research: focus on the individual. Pharm Res 12:943-944, 1995.
473. Stoughton RB. Penetration of drugs through skin. Dermatologica 152(suppl 1):27-36, 1976.
474. Blackwelder WC. Proving the null hypothesis in clinical trials. Controlled Clin Trials 3:345-353, 1982.
475. Gibson JR, Kirsch JM, Darley CR, Harvey SG, Burke CA, Hanson ME. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol 111(suppl 27):204-212, 1984.
476. Barry BW, Fyrand O, Woodford R, Ulshagen K, Hogstad G. Control of bioavailability of a topical steroid; comparison of desonide creams 0.05% and 0.1% by vasoconstrictor studies and clinical trials. Clin Exp Dermatol 12:406-409, 1987.
477. Martin GP. The effect of dose under a hydrocolloid patch on the human bioavailability of a topical corticosteroid. J Pharm Pharmacol 41:129P, 1989.
478. Kecskes A, Jahn P, Wendt H, Lange L, Kleine Kuhlmann R. Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers. Eur J Clin Pharmacol 43:157-159, 1992.
479. Gibson JR. Effect of concentration on the clinical potency of corticosteroid ointment formulations. Skin Pharmacol 1:214-222, 1987.
480. Surber C, Davis A, Rufli T. Factors influencing topical bioavailability: New concept of topical dosing. Dermatology 191:173, 1995.
481. Marples and Kligman. 1973. Rec No 26240
482. Stenberg C, Larko O. Sunscreen application and its importance for the sun protection factor. Arch Dermatol 121:1400-1402, 1985.